Pioneering neuroprotection using acute omega-3
fatty acid therapeutics
Brain cell death following hypoxia-ischemia is inhibited by the pleiotropic effects of bioactive omega-3 fatty acids
See More
THDG3 is a novel semi-synthetic omega-3
fatty acid glyceride emulsion
Intravenous THDG3 is a potent neuroprotectant and far superior to any tested omega-3 triglyceride emulsion
See More
The rare neonatal condition HIE is the lead
indication for THDG3
Neonatal hypoxic-ischemic encephalopathy (HIE) is the medical term for brain damage in newborns who have received too little oxygen during labor and/or delivery
See MoreTHDG3
THDG3:
A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline
THDG3
THDG3:
A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline
Indications
Neonatal hypoxic-ischemic encephalopathy (HIE)
Insufficient supply of oxygen during labor and/or delivery causes brain injury in tens of thousands of newborns every year. HIE is the most common cause of cerebral palsy in full-term infants
Indications
Ischemic stroke is the 5th most common cause of death in the US
Ischemic stroke is one of the largest and most costly unmet medical needs. Tissue plasminogen activator (t-PA) and thrombectomy can be used to restore blood flow in some patients but no neuroprotectant is approved to date
Partnering
DeckTherapeutics seeks to partner its omega-3 platform
Contact us to discuss how we together can leverage DeckTherapeutics’ world class expertise and IP in the area of acute omega-3 therapeutics
Partnering
DeckTherapeutics seeks to partner its omega-3 platform
Contact us to discuss how we together can leverage DeckTherapeutics’ world class expertise and IP in the area of acute omega-3 therapeutics